Home / Market News / $PRME
fiscal.ai Corporate Catalyst Impact 55/100 ● neutral

Oppenheimer Maintains Buy Rating on Prime Medicine

Nov 14, 2026, 2:07 PM UTC · Primary ticker $PRME

Oppenheimer analyst Kostas Biliouris reiterated a Buy rating and an $11 price target for Prime Medicine. The analyst highlighted that recent financing activities have removed a significant overhang, potentially leading to upside opportunities for the company by 2027.

Oppenheimer analyst Kostas Biliouris reaffirmed a 'Buy' rating and an $11 price target for Prime Medicine (PRME). This reiteration comes with commentary suggesting that the company's recent financing activities have successfully addressed a major concern for investors. This removal of an 'overhang' is seen as a positive development, potentially paving the way for upside opportunities for PRME in the longer term, specifically by 2027. For traders, this indicates a potential long-term positive sentiment shift, though the immediate short-term impact might be moderate as it's a reiteration rather than new news. The key opportunity lies in the analyst's view that a significant hurdle has been cleared, which could attract more investors looking for future growth.

$PRME positive Analyst reiterates Buy rating and price target, notes financing removed overhang
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.